Stockscreener 앱 받기
7.14
2.59%
-0.19
시간 외 거래:
7.15
0.01
+0.14%
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan
Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant - Stock Titan
Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30 - Stock Titan
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant - Stock Titan
Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options - Stock Titan
Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options - Stock Titan
Arcturus Therapeutics highlights mRNA pipeline, CF data and vaccine expansion at Jefferies - MSN
Behavioral Patterns of ARCT and Institutional Flows - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. 2026 Annual Shareholder Meeting Results and Election of Directors - Minichart
Arcturus Shareholders Back Board, Pay, and Auditor - TipRanks
Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor - Stock Titan
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - Barchart.com
Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next - Bez Kabli
Arcturus Therapeutics Holds Steady at $7.92 as Market Awaits CatalystsMomentum ETF - newsline.com
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Arcturus Therapeutics Poised for a Massive Upside in 2026 - Kavout
Arcturus Therapeutics (ARCT) Holds Steady at $7.92 – Waiting for a CatalystTriple EMA - newsline.com
Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026 - Traders Union
Arcturus Therapeutics (ARCT) Surges 6.2% as Buyers Defend Key SupportFibonacci Extension - thelegaladvocate.com
Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment - Traders Union
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
mRNA drug maker Arcturus hits Jefferies 2026 healthcare stage in New York - Stock Titan
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings: Narrower Net Loss Beats Estimates Amid Pipeline ProgressEarnings Miss Streak - newsline.com
ARCT Q1 2026 Earnings: Arcturus Beats EPS Estimates Amid Pre‑Revenue Phase, Stock Edges HigherQuarterly Earnings Report - newsline.com
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - Moomoo
How (ARCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting - Traders Union
Arcturus Therapeutics Holdings Inc (NQ: ARCT - FinancialContent
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - MSN
ARCTURUS THERAPEUTICS HOLDINGS INC UPSWING STARTED | ARCT STOCK NEWS (VWpPDIK5Ud) - fathomjournal.org
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2026 Earnings Call Transcript - Insider Monkey
MSN Money - MSN
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call - GuruFocus
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Should I Buy - Intellectia AI
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline - Investing.com
Trading Systems Reacting to (ARCT) Volatility - Stock Traders Daily
ARCT: Advanced rare disease pipeline, reduced expenses, and strong cash position support 2026 milestones - TradingView
ARCT: Achieved key clinical milestones in rare disease mRNA programs with strong financial runway - TradingView
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff - Bitget
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline - TipRanks
Arcturus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances - ChartMill
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics (ARCT) CFO granted 100,000 stock options - Stock Titan
[Form 3] Arcturus Therapeutics Holdings Inc. Initial Statement of Beneficial Ownership - Stock Titan
Q1 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics (NASDAQ: ARCT) Q1 2026 hit by 93% revenue drop - Stock Titan
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revenue plunge and leadership change at Arcturus (NASDAQ: ARCT) - Stock Titan
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT) - Stock Titan
1.27%
1.43%
자본화:
|
볼륨(24시간):